Details of the Drug Combination

General Information of Drug Combination (ID: DCD9SDL)

Drug Combination Name
Brincidofovir Triiodothyronine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Brincidofovir   DMS0PND Triiodothyronine   DM14NKM
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 4.5
Bliss Independence Score: 4.5
Loewe Additivity Score: 5.5
LHighest Single Agent (HSA) Score: 5.54

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076923.
4 ClinicalTrials.gov (NCT04348513) Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection. U.S. National Institutes of Health.